Newly-Opened Clinical Trial for People with Acute Myeloid LeukemiaPosted: May 28, 2017
Dr. Gail J. Roboz is the principal investigator for a new immunotherapy clinical trial at Weill Cornell Medicine and NewYork-Presbyterian for people with acute myeloid leukemia (AML). The clinical trial is evaluating engineered CAR-T cells, UCART123, that have been specially engineered in the laboratory to be able to target a molecule on the surface of leukemia cells called CD123. It is hoped that the T cells will be able to destroy the CD123 positive leukemia cells and lead to remission in selected patients with AML.
Contact us or click here to learn more: http://bit.ly/2rpQso8